Validation of standardized questionnaires for depression (WHO-5, PHQ-9, BDI-II) for rheumatoid arthritis and study of the frequency of depression in RA

Validation of standardized questionnaires for depression (WHO-5, PHQ-9, BDI-II) for rheumatoid arthritis and study of the frequency of depression in RA - VADERA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003231

Enrollment

1300

Registered

2011-08-15

Start date

2012-01-13

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M05 M06.0

Interventions

Group 1: Part I: Survey of patients with rheumatoid arthritis using a questionnaire for depression. Part II: analysis of incidence of depression in RA patients with validated questionnaires

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: confirmed rheumatoid arthritis

Exclusion criteria

Exclusion criteria: confirmed depression, secondary pain syndrome (fibromyalgy) in the second part of the study

Design outcomes

Primary

Measure	Time frame
Part I: Validation of a depression score (WHO-5 = Well-Being-Index of the world health organisation, PHQ-9 - = Patient Health Questionnaire Depression with 9 questions, BDI-II = Beck's depression inventar) for rheumatoid arthritis	—

Secondary

Measure	Time frame
Part II: Measure incidence of depression in rheumatoid arthritis with a validated instrument	—

Countries

Germany

Contacts

Public ContactHeike Berthold

Roche Pharma AG

heike.berthold@roche.com07624-142974

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 21, 2026